Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$3.56 USD

3.56
172,918

-0.10 (-2.73%)

Updated Jun 6, 2024 04:00 PM ET

After-Market: $3.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 45.57% and 16.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotech (PBYI) Down 44% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma Biotech's (PBYI) Nerlynx Aids Growth Despite Competition

by Zacks Equity Research

Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. High dependence on Nerlynx for growth remains a woe.

Puma (PBYI) Stock Down Despite Q4 Earnings & Sales Beat

by Zacks Equity Research

Puma Biotech (PBYI) incurs narrower loss in Q4 and tops sales estimates. Sales of Nerlynx decline year over year. Stock drops 10%.

Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth

by Zacks Equity Research

Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.

Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.

Blueprint Medicines Initiates Dosing in Liver Cancer Study

by Zacks Equity Research

Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.

Why Is Puma Biotech (PBYI) Down 1% Since Last Earnings Report?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma Biotech Expands Pierre Fabre License to Add Countries

by Zacks Equity Research

Puma Biotech (PBYI) stretches its license deal with Pierre Fabre, granting the latter commercial rights to Nerlynx in new countries across Europe and parts of Africa. Stock rallies.

Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.

Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down

by Zacks Equity Research

Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.

Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.11% and -7.43%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Puma Biotech (PBYI) Q3 Earnings Expected to Decline

by Zacks Equity Research

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx

by Zacks Equity Research

The FDA approves the label update of Puma Biotech's (PBYI) breast cancer drug Nerlynx in order to add data from the CONTROL study. Stock gains.

Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.

Roche's New Perjeta Combo Meets Goal in Breast Cancer Study

by Zacks Equity Research

Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.

Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance

by Zacks Equity Research

The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.

Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up

by Zacks Equity Research

Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.

ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.

Puma Biotech (PBYI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Puma Biotech (PBYI) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.

Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx

by Zacks Equity Research

Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.

Puma Biotech (PBYI) Down 53.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.